Chinese biotech firms are entering a period of rapid growth, with combined revenues topping 500 billion yuan in 2025—a 9.3% year‑on‑year rise and net profit soaring 46.4% to 42.34 billion yuan in the first quarter of 2026. This momentum is driven by a wave of new drug launches, expanding global partnerships, and the winding down of generic‑drug price cuts. At the 2026 ASCO meeting in Chicago (May 29‑June 2), BeiGene will showcase 24 abstracts, including Phase 3 data on its CDK4 inhibitor BGB‑43395 for HR+/HER2‑ breast cancer and Phase 1 results for its B7‑H4 ADC BG‑C9074 in ovarian and solid tumors. Other highlights feature a bispecific antibody for liver cancer and a PD‑L1 analysis of Zanidatamab in HER2‑positive gastro‑esophageal cancer, underscoring China’s growing confidence in solid‑tumor breakthroughs. In a parallel development, Hengrui Medicine signed a global licensing deal with Bristol‑Myers Squibb to co‑develop 13 early‑stage oncology, hematology and immunology projects, accelerating the pipeline for patients worldwide. Investors are taking note of the Hong Kong‑listed Innovative Drug ETF JingShun (513780), which tracks the CSI Hong Kong Stock Connect Innovative Drug Index. The fund has outperformed its benchmark with a 36% net‑value gain over the past year, low management fees (0.50%) and strong daily trading volume, making it a convenient way to tap into China’s high‑growth biotech sector.
Read moreOver the past two decades China has raced from Nobel‑level discoveries in stem‑cell science to bustling hospital clinics offering cell and gene therapies. A new set of rules released in March 2024 finally draws a line between “drugs” and “translatable biomedical technologies,” allowing highly personalized or rare‑disease treatments that lack a domestic drug counterpart to be classified as technology rather than medicine. This regulatory clarity has unleashed a flood of investigator‑initiated trials (IITs). From 2015 to the end of 2025 the number of IITs in China’s cell‑gene‑therapy (CGT) field jumped twelve‑fold to more than 1,300 projects, enrolling over 30,000 patients—far outpacing traditional registered trials. Major tertiary hospitals have responded by opening dedicated cell‑regenerative outpatient clinics and are eager to launch more IITs. While the promise is alluring—large‑scale indications could bring tens of millions of yuan in revenue for hospitals—the reality is mixed. Early hype suggested cures and anti‑aging miracles, yet systematic data on efficacy and safety remain scarce. Companies remain cautious; the technology pathway still involves lengthy approvals after costly R&D. Experts say the next decade will be defined by how quickly the industry can turn rapid IIT successes into vetted, affordable therapies for patients across China.
Read more